Clinical Trial Update: A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 study of RC18 administered subcutaneously to subjects with primary IgA nephropathy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Primary IgA Nephropathy | Phase 2 | Status: COMPLETED